JP6423750B2 - 造影剤腎症の発生を予防するための飲料又はゼリー - Google Patents
造影剤腎症の発生を予防するための飲料又はゼリー Download PDFInfo
- Publication number
- JP6423750B2 JP6423750B2 JP2015081935A JP2015081935A JP6423750B2 JP 6423750 B2 JP6423750 B2 JP 6423750B2 JP 2015081935 A JP2015081935 A JP 2015081935A JP 2015081935 A JP2015081935 A JP 2015081935A JP 6423750 B2 JP6423750 B2 JP 6423750B2
- Authority
- JP
- Japan
- Prior art keywords
- meq
- contrast
- nephropathy
- contrast agent
- beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
K+ 10〜30 mEq/L
Cl− 10〜70 mEq/L
Mg2+ 1.9〜2.1 mEq/L
リン 1.9〜2.1 mmol/L
乳酸 15〜33 mEq/L
K+ 10〜30 mEq/L
Cl− 10〜70 mEq/L
Mg2+ 1.9〜2.1 mEq/L
リン 1.9〜2.1 mmol/L
乳酸 15〜33 mEq/L
本発明において、高血圧とは、循環系障害等の障害を誘発するおそれのあるレベルにまで全身の動脈圧が一過性又は持続的に高くなる状態を意味する。高血圧の具体的な定義は特に限定されないが、例えば、日本高血圧学会が定めた、「高血圧治療ガイドライン2004」(JSH2004)に準拠し、収縮期血圧/拡張期血圧が140/90mmHg以上である状態を意味する。降圧薬等を服用していない状態で、収縮期血圧が140mmHg以上であり、拡張期血圧が90mmHg以上である場合に加えて、収縮期血圧が140mmHg未満であるが、拡張期血圧が90mmHg以上である場合や、拡張期血圧が90mmHg未満であるが、収縮期血圧が140mmHg以上である場合も含まれる。
K+ 20 mEq/L
Cl− 50 mEq/L
Mg2+ 2.0 mEq/L
リン 2.0 mmol/L
乳酸 31 mEq/L
実施例としての飲料は、造影剤投与前に500ml、造影剤投与後に1000mlを経口投与した。比較例として造影剤投与から24時間後に努力飲水(1500ml)を投与した。実施例と比較例とにおいて15名ずつの患者で試験した。結果を下記表1に示す。
Claims (4)
- 高血圧患者に対する造影剤の投与前及び投与後に飲用される造影剤腎症の発生を予防するための飲料又はゼリーであって、
下記の成分を含有し、ナトリウムイオンとブドウ糖のモル比が1:1.5〜3.0であることを特徴とする飲料又はゼリー。
Na+ 20〜60 mEq/L
K+ 10〜30 mEq/L
Cl− 10〜70 mEq/L
Mg2+ 1.9〜2.1 mEq/L
リン 1.9〜2.1 mmol/L
乳酸 15〜33 mEq/L - 更に、Ca2+0.1〜3.0mEq/Lを含有することを特徴とする請求項1に記載の飲料又はゼリー。
- 前記高血圧患者は、収縮期血圧/拡張期血圧が140/90mmHg以上である状態の患者であることを特徴とする請求項1又は2に記載の飲料又はゼリー。
- 前記造影剤腎症は、造影剤曝露3日以内にSCr値が0.5mg/dL以上増加するものであることを特徴とする請求項1乃至3の何れか1項に記載の飲料又はゼリー。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015081935A JP6423750B2 (ja) | 2015-04-13 | 2015-04-13 | 造影剤腎症の発生を予防するための飲料又はゼリー |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015081935A JP6423750B2 (ja) | 2015-04-13 | 2015-04-13 | 造影剤腎症の発生を予防するための飲料又はゼリー |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016199517A JP2016199517A (ja) | 2016-12-01 |
JP6423750B2 true JP6423750B2 (ja) | 2018-11-14 |
Family
ID=57423991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015081935A Active JP6423750B2 (ja) | 2015-04-13 | 2015-04-13 | 造影剤腎症の発生を予防するための飲料又はゼリー |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6423750B2 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007521233A (ja) * | 2003-08-05 | 2007-08-02 | フロウメディカ, インコーポレイテッド | 放射線造影剤誘発性腎症の予防のためのシステムおよび方法 |
US7938817B2 (en) * | 2004-09-09 | 2011-05-10 | Plc Medical Systems, Inc. | Patient hydration system and method |
JP5986729B2 (ja) * | 2011-10-17 | 2016-09-06 | 公益財団法人ヒューマンサイエンス振興財団 | 造影剤及び造影剤キット |
-
2015
- 2015-04-13 JP JP2015081935A patent/JP6423750B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016199517A (ja) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yonas et al. | Stable xenon CT blood flow mapping for evaluation of patients with extracranial-intracranial bypass surgery | |
Dalakos et al. | “Malignant” hypertension resulting from atheromatous embolization predominantly of one kidney | |
Morgan et al. | Aggressive management of aneurysmal subarachnoid haemorrhage based on a papaverine angioplasty protocol | |
US8153164B2 (en) | Method for attenuating free radical formation resulting from a bodily insult | |
JP6423750B2 (ja) | 造影剤腎症の発生を予防するための飲料又はゼリー | |
Zimmermann et al. | Feasability of contrast-enhanced ultrasound with image fusion of CEUS and MS-CT for endovascular grafting in infrarenal abdominal aortic aneurysm in a single patient | |
Kälsch et al. | Gadolinium‐based coronary angiography in patients with contraindication for iodinated x‐ray contrast medium: A word of caution | |
Roh et al. | Practicing safe use of nonionic, low-osmolarity iodinated contrast | |
Besci et al. | Wernicke encephalopathy and lactic acidosis in thiamine deficiency | |
Patel et al. | Idiopathic arterial calcification in childhood | |
JP5986729B2 (ja) | 造影剤及び造影剤キット | |
WO2005115415A1 (en) | Method for attenuating free radical formation resulting from a bodily insult | |
Kondo et al. | Hemodialysis-related portal-systemic encephalopathy | |
IDO et al. | Iohexol cerebral angiography: multicenter clinical trial | |
Kundan et al. | Outcomes of management of patients with acute mesenteric ischemia: a prospective study | |
Katholi | Contrast-induced nephropathy-choice of contrast agents to reduce renal risk | |
Bowman et al. | Common Clinical Problems in Hemodialysis | |
Budincevic et al. | Bilateral subclavian steal syndrome in an intensive care unit. A case report. | |
Clark-Cutaia | Variation in Hemodialysis Patient Body Composition as a Result of Recommended Dietary Sodium Intake Restriction. | |
Dharnidharka et al. | Role of Radiological Assessment and Intervention in Pediatric Dialysis | |
Sheth et al. | Calciphylaxis Secondary to End Stage Renal Disease | |
Bartlett Ellis | Feasibility of an Intervention to Slow Progression of Chronic Kidney Disease. | |
Duc | CLINICAL CHARACTERISTICS, COMPLICATIONS IN 39 PATIENTS WITH CEREBRAL ANEURYSM AFTER ENDOVASCULAR COILING IN THE FIRST 24 HOURS, AT MILITARY HOSPITAL 103 | |
Landoni et al. | Mitral valve surgery and acute renal failure | |
Clark-Cutaia | Perceived Barriers to Adherence to Dietary Sodium Recommendations in Hemodialysis Patients. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181009 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181019 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6423750 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |